Datta Rupak, Juthani-Mehta Manisha
Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Palliat Care. 2017 Dec 19;10:1178224217749233. doi: 10.1177/1178224217749233. eCollection 2017.
Palliative care includes comprehensive strategies to optimize quality of life for patients and families confronting terminal illness. Infections are a common complication in terminal illness, and infections due to multidrug-resistant organisms (MDROs) are particularly challenging to manage in palliative care. Limited data suggest that palliative care patients often harbor MDRO. When MDROs are present, distinguishing colonization from infection is challenging due to cognitive impairment or metastatic disease limiting symptom assessment and the lack of common signs of infection. Multidrug-resistant organisms also add psychological burden through infection prevention measures including patient isolation and contact precautions which conflict with the goals of palliation. Moreover, if antimicrobial therapy is indicated per goals of care discussions, available treatment options are often limited, invasive, expensive, or associated with adverse effects that burden patients and families. These issues raise important ethical considerations for managing and containing MDROs in the palliative care setting.
姑息治疗包括一系列综合策略,旨在为面临绝症的患者及其家属优化生活质量。感染是绝症患者常见的并发症,而耐多药微生物(MDRO)引起的感染在姑息治疗中尤其难以处理。有限的数据表明,姑息治疗患者常常携带耐多药微生物。当存在耐多药微生物时,由于认知障碍或转移性疾病限制了症状评估且缺乏感染的常见体征,区分定植与感染具有挑战性。耐多药微生物还通过感染预防措施增加心理负担,这些措施包括患者隔离和接触预防,这与姑息治疗的目标相冲突。此外,如果根据护理讨论的目标需要进行抗菌治疗,可用的治疗选择通常有限、具有侵入性、昂贵,或伴有给患者及其家属带来负担的不良反应。这些问题为在姑息治疗环境中管理和控制耐多药微生物提出了重要的伦理考量。